HomeInvesting NewsGSK announces an upcoming FDA AdCom conference on the treatment of renal...

GSK announces an upcoming FDA AdCom conference on the treatment of renal disease

Published on

GSK plc (NYSE:GSK)

An impartial panel of FDA specialists will convene in October to review the company’s marketing application for daprodustat, an oral treatment for people with anemia caused by chronic kidney disease (CKD), according to a Tuesday statement from GSK plc (NYSE:GSK).

Daprodustat, which is a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) with a PDUFA action date of February 1, 2023, is now being reviewed by the FDA for chronic kidney disease.

On October 26, 2022, the FDA’s Cardiovascular and Renal Drugs Advisory Committee is scheduled to meet to discuss GSK’s (GSK) daprodustat NDA.

According to Chris Corsico, senior vice president of development at GSK, “we believe daprodustat and the outcomes exhibited in the ASCEND clinical trial program have tremendous potential for individuals living with CKD anemia who presently do not have an oral therapy choice.” Data from the ASCEND phase III program support the company’s marketing application for daprodustat.

Phase III clinical research program for ASCEND

The ASCEND program involves five phases III investigations in order to evaluate daprodustat’s effectiveness and safety profile for the management of CKD-related anemia across the illness spectrum. Over 8,000 patients were enrolled in the program, and they received to care for a maximum of 4.26 years. At Kidney Week 2021, sponsored by the American Society of Nephrology, findings from all five trials were presented.

ASCEND-ND and ASCEND-D, two crucial cardiovascular outcomes studies that looked at patients who were not on dialysis and who were on dialysis, respectively, also published their findings in the New England Journal of Medicine.

Relating to chronic kidney disease and anemia

The impact on global public health of CKD, which is characterized by a progressive decrease in renal function, is rising. Hypertension, diabetes, obesity, and primary renal diseases are all risk factors for CKD.

About GSK

GSK is a multinational biopharmaceutical business with the mission of bringing talent, technology, and science together to fight disease.

Read more about the press release.

Featured Image – Megapixl © Kadmy

See Disclaimer Please

Latest News

Meta Stock Slides as Firm Tests New Account Switching, Facebook, and Instagram Navigation

Meta stock today traded at 137.37 as of 03:40 PM EDT on Sept 26 For...

The Cause of Monday’s Amazon Stock Rally

Amazon Stock (NASDAQ:AMZN) Amazon stock was up as much as 3.1% on Monday morning. The...

The Reason Why AMC Stock Is Falling Today

AMC Stock (NYSE:AMC) On Monday morning, news of the company's newly minted AMC Preferred Equity...

Twilio Stock: The Upside of a Down Day

Twilio Stock (NYSE:TWLO) Though a new week has begun, the stock market continues to show...

More like this

Verizon Stock Price Falls After Company Announces Aid for Puerto Rico Disaster Relief.

Verizon Stock (NYSE:VZ) Verizon stock declined after announcing it has pledged $100,000 to the American...

Alphabet Stock Rises as the Launch of New Pixel Smartphones and the Pixel Watch Are Anticipated Next Week

Alphabet stock was trading at $99.12 at 11:50 AM EDT Next week, Google (NASDAQ:GOOG) (NASDAQ:GOOGL)...

Raytheon Stock Plunged After It Said It Won a $160 Million Contract for a Dual-Band Radar.

Raytheon Stock (NYSE:RTX) Raytheon stock declined after the company announced that it had just won...

Jblu Stock up and Joins American Airlines to Defend Their Alliance in Court

JBLU stock was up, trading at 6.99 as of 10:21 AM EDT on Monday The...

Target Stock Falls as the Retailer Promised to Provide Excellent Holiday Savings and Values.

Target Stock (NYSE:TGT) To match the excitement of holiday customers, stores have started preparing for...

Lyft Stock Drops as Ubs Lowers Its Ratings and Slashes Its Forecast

Lyft stock slightly slid to $13.72 at 10:07 AM EDT on Monday. On Monday, Lyft...